Annals of Internal Medicine. 1991;114:
|
|
- Mae King
- 5 years ago
- Views:
Transcription
1 Serologic Response to Treatment of Infectious Syphilis Barbara Romanowski, MD; Ruth Sutherland, DPH, RN; Gordon H. Fick, PhD; Debbie Mooney, BSc; and Edgar J. Love, MD, PhD Objective: To evaluate the serologic response to treatment of patients with infectious syphilis. Design: Historical cohort study of all cases of infectious syphilis in Alberta from 1981 to Patients: A total of 1090 patients were entered; 857 with primary syphilis, 183 with secondary syphilis, and 50 with early latent disease. Two hundred and eight patients were excluded who either were pregnant, had negative serologic results before treatment, had clinical relapse, were treatment failures, or were lost to follow-up. Interventions: All 882 evaluable patients were treated with a recommended antibiotic regimen for infectious syphilis and returned for re-assessment including repeat serologic testing. Measurements and Main Results: Seventy-two percent (95% CI, 66% to 77%) and 56% (CI, 43% to 70%) of patients with initial episodes of primary or secondary syphilis had seroreverted according to rapid plasma reagin (RPR) test results by 36 months. A 2- and 3-tube decline was seen by 6 and 12 months in primary and secondary syphilis. Early latent syphilis resulted in only a 2-tube decrease at 12 months. Serologic response was not affected by sex, age, race, or sexual orientation. Patients with their first infection were more likely to experience RPR seroreversal than those with repeat infections. The RPR reversal rates also depended on the pretreatment titer and stage of disease. At 36 months, 24% (CI, 20% to 28%) of patients had nonreactive fluorescent treponemal antibody absorption tests (FTA-Abs), and 13% (CI, 11% to 15%) had nonreactive microhemoglutination tests for Treponema pallidum (MHA-TP). Conclusions: Adequate therapeutic response for syphilis must be based on illness episode and the pretreatment RPR titer. Treponemal tests can demonstrate seroreversion after 36 months, and a negative treponemal test does not rule out a past history of syphilis. Annals of Internal Medicine. 1991;114: From STD Control, Alberta Health, Edmonton, Alberta; and the University of Calgary, Calgary, Alberta, Canada. For current author addresses, see end of text. Phy sicians diagnose infectious syphilis on the basis of clinical findings, examination of lesion material for Treponema pallidum, and serologic tests for syphilis. Penicillin and tetracycline regimens are highly effective for treatment of early syphilis (1, 2). No simple test is available that determines that syphilis has been cured within days or weeks after treatment. To assess treatment, the patient is asked to return for repeat serologic testing and clinical evaluation at varying intervals, usually at 3, 6, and 12 months. It has been reported that seroreversion is more rapid after therapy if the duration of infection or clinical lesions is short and if the initial nontreponemal titer is low. It has also been stated, however, that the rate of decline of high-titer reactivity is more rapid after treatment than the rate of decline of lower-titer seroreactivity (3). When the serologic test becomes negative, the patient is considered cured. However, when it remains positive, a clinical dilemma arises. In patients presenting with their first episode of early syphilis, titers can be expected to decline fourfold (2 dilutions) within 3 months of therapy and eightfold (3 dilutions) by 6 months (4). In patients with previous syphilis who become re-infected or in patients with late syphilis, the serologic response is often slower. We were able to examine the serologic response to treatment of patients with infectious syphilis because from 1983 to 1985 the province of Alberta experienced a sudden, sustained epidemic of infectious syphilis that primarily affected the heterosexual community. Patients and Methods In Alberta, standard guidelines for the diagnosis, treatment, and follow-up of sexually transmitted diseases are regulated and enforced by Sexually Transmitted Disease Control, Alberta Health. All patients with syphilis are diagnosed and staged on the basis of clinical and serologic findings. The serum specimens are processed by the Provincial Laboratory of Public Health in either Edmonton or Calgary. The rapid plasma reagin (RPR) test, the microhemoglutination test for Treponema pallidum (MHA-TP), and the fluorescent treponemal antibody absorption (FTA-Abs) test are done in accordance with standard procedures. Over 90% of patients with infectious syphilis receive benzathine penicillin (2.4 million units as a single dose), and the remainder receive either tetracycline or erythromycin (500 mg orally four times daily for at least 15 days). All patients are advised to return for follow-up serologic testing. Sexual partners, when identified and located, are treated prophylactically. Our study sample included patients with infectious syphilis (primary, secondary, or early latent syphilis) diagnosed and treated in the Province of Alberta from 1981 to Seventeen women who were treated for infectious syphilis either during pregnancy or postpartum were excluded because one would expect them to respond differently due to immunologic changes that occur during pregnancy. Primary syphilis was diagnosed on the basis of the presence of Treponema pallidum on darkfield microscopy from mucocu American College of Physicians 1005
2 Table 1. Cumulative Rapid Plasma Reagin (RPR) Seroreversion after Treatment for Infectious Syphilis by Stage and Illness Episode Stage Illness Episode At 3 At 6 At 12 At 24 At 36 Months Months Months Months Months Primary Secondary Early latent Initial* Cumulative proportion ± SE 12.8 ± ± ± ± ± 2.7 Patients, «t Repeat Cumulative proportion ± SE ± ± ± ± 7.4 Patients, n Initial* Cumulative proportion ± SE 0.7 ± ± ± ± ± 6.7 Patients, n Initial Cumulative proportion ± SE 3.0 ± ± ± ± ± 13.8 Patients, n * Difference between stages for initial illness episode over 36 months using the Lee-Desu statistic; P < t Number of patients with a reactive RPR titer entering the time interval. t Difference between stages for initial illness episode over 36 months using the Lee-Desu statistic; P = taneous, genital, or rectal lesions or recent seroconversion of syphilis serologic tests together with clinical findings of a primary chancre. Secondary syphilis was diagnosed in patients with a reactive serologic test who had either typical macular or papular rashes on their palms and soles, mucous membrane lesions, or darkfield positive condylomata lata. Asymptomatic patients with reactive serologic findings and a history of sexual contact within the past year with a person who had primary or secondary syphilis were designated as having early latent disease. The patients with early latent disease may also have had a clinical history of untreated primary or secondary syphilis in the past year. To be included in this study, all patients must have had a reactive serologic test at or no more than 21 days before the start of treatment and one or more serologic tests after treatment. The relevant demographic, clinical, and serologic data were collected by a retrospective chart review of records held by Sexually Transmitted Disease Control, Alberta Health. All data were analyzed using the SPSS Statistical Analysis System on the mainframe computing facilities of the University of Calgary. Except for the cross-tabulations and frequency distributions, all analyses were based on life-table methods (5). In these analyses, the terminal event was either seroreversal or a specified decrease in quantitative RPR dilutions. Censored cases included those patients lost to follow-up, those who had clinical relapse with or without re-exposure, and those who failed treatment. Treatment failure was defined as a fourfold rise in the RPR titer after therapy without re-exposure. For descriptive purposes, the survival curves were compared using the Lee-Desu statistic as a test of significance. Confidence intervals (CIs) of 95% are provided where appropriate. Results From 1981 through 1987, the province of Alberta recorded 1090 cases of infectious syphilis. Of these, 857 patients had primary syphilis, 183 had secondary syphilis, and 50 had early latent disease. Most of the cases (834, or 76%) were recorded during the epidemic from 1983 to Homosexual and bisexual men accounted for 186 (17%) of the total cases from 1981 to 1987 and for 102 cases (12%) during the epidemic years. The human immunodeficiency virus (HIV) status of these men is unknown, as is the proportion of intravenous drug users. Change in RPR Titers This analysis was restricted to 882 cases of infectious syphilis (primary syphilis, 602; secondary syphilis, 161; early latent syphilis, 38). The remaining 208 patients were not analyzed on the basis of previously outlined exclusion criteria. At the end of 36 months, the cumulative proportion showing seroreversal was 63% ± 3%. The seroreversion rate was highest in patients experiencing their first illness episode with a diagnosis of primary syphilis: 72% at the end of 36 months (Table 1). The seroreversion rate was lower in those persons with a repeat episode of primary syphilis (34% at 36 months) and in those experiencing their initial illness episode with either secondary syphilis (56% at 36 months) or early latent syphilis (26% at 36 months). None of the patients experiencing a repeat illness with either secondary syphilis (13 patients) or early latent syphilis (2 patients) seroreverted. Among those patients having their first illness episode, the cumulative proportion of seroreversion varied directly with the initial RPR titer (Table 2). This effect was most marked in those with a diagnosis of primary syphilis. In patients with secondary syphilis, the proportion with seroreversion was comparable to those with an initial RPR titer of less than or equal to 1:8 or (60% and 68%, respectively), and very low (19%) in those with an initial titer of 1:256 or greater. Seroreversal in patients with early latent syphilis only occurred when the initial titer was 1:8 or less. Significant differences were found by sex and race in the cumulative proportion of seroreversion among those with their first illness episode with primary syphilis. Stratification by initial RPR titer, however, eliminated these differences (data not shown). Neither age nor sexual orientation influenced the cumulative proportion of seroreversal. There were too few patients in the other diagnostic groups to allow similar analysis. Because of the large number of patients with infectious syphilis who did not achieve seroreversal, we examined the decrease in RPR dilutions (Table 3) in patients with their initial illness episode and in patients with secondary or early latent syphilis only when the number of cases was adequate. Although these life-table analyses were carried out for the entire 36 months of follow-up, the diminishing sample size limits meaningful discussion beyond 24 months. For patients with primary syphilis (regardless of the June 1991 Annals of Internal Medicine Volume 114 Number 12
3 initial RPR titer) more than 75% had a 2-tube or greater (dilutions) reduction in RPR titer by 6 months (Table 3). By 24 months, 97% of patients had reached this end point. Three- and four-tube decreases occurred more slowly: Approximately 66% of patients achieved a 3-tube or greater decrease by 6 months but at 24 months the cumulative proportions were comparable. In patients with secondary syphilis, the decrease in RPR titers occurred somewhat earlier, by initial RPR titer, than in those with primary syphilis: Eighty percent of patients achieved a 3-tube or greater decrease by 6 months. The proportion of patients with early latent syphilis had low rates of titer decrease. Change in Confirmatory Treponemal Tests The confirmatory treponemal tests were less likely to serorevert (Table 4). All patients whose MHA-TP or FTA-Abs test results seroreverted were experiencing their first episode of illness. No patients with early latent syphilis seroreverted. All but three of the MHA-TP and all of the FTA-Abs seroreversions occurred in persons with primary syphilis. For those with their first illness episode of primary syphilis, only 8% of those with reactive MHA tests and 11% of those with reactive FTA tests had become negative at 12 months. After 3 years of follow-up, these figures were only 13% and 24% for the MHA-TP and FTA-Abs tests, respectively. The seroreversion rate was not influenced by sex, age, race, or by sexual preference among men. Discussion Clinicians depend on serologic evaluation to determine the efficacy of syphilis therapy. The patient may come for only one or two follow-up visits, however, and little information on temporal trends is available. This study provides data on seroreversion rates and titer decreases by stage of disease, initial RPR titer, and disease episode. We found that sex, age, race, and sexual orientation did not affect the serologic response. In our province, HIV infection has primarily affected homosexual and bisexual men. In 1985, the prevalence of HIV infection in this group was very low. However, we did find that illness episode was significant in predicting serologic response. Individuals with their first infection were more likely to serorevert than those with re-infections regardless of the stage of disease. Patients with first infections also seroreverted earlier. Similar findings have been described by Brown and colleagues (4). The RPR seroreversal rates depend on the pretreatment titer as well as on the stage of infection. Depending on the initial RPR titer, patients with primary syphilis had seroreversion rates of 6% to 70% at 12 months. Secondary syphilis seroreversion rates were much slower, reaching a high of 68% at 36 months. The higher the initial titer, the less likely seroreversion was to occur in primary and secondary syphilis. For persons with early latent disease, only those whose initial titer was 1:8 or less had significant seroreversal rates, and Table 2. Cumulative Rapid Plasma Reagin (RPR) Seroreversion after Treatment for Initial Episode of Infectious Syphilis by Stage and Pretreatment RPR Dilutions Stage Pretreatment RPR Dilution At 3 Months At 6 Months At 12 Months At 24 Months At 36 Months Primary* < 1:8 Cumulative proportion ± SE 26.3 ± ± ± ± ± 2.8 Patients, nt Cumulative proportion ± SE 2.7 ± ± ± ± ± 4.5 Patients, n Cumulative proportion ± SE ± ± ± ± 10.2 Patients, n Secondary* < 1:8 Cumulative proportion ± SE 20.0 ± ± ± ± ± 21.9 Patients, n Cumulative proportion ± SE ± ± ± ± 7.3 Patients,/? Cumulative proportion ± SE ± ± 12.1 Patients, n Early latent < 1:8 Cumulative proportion ± SE 6.9 ± ± ± ± ± 25.6 Patients, n Cumulative proportion ± SE Patients, n Cumulative proportion ± SE Patients, n * Difference between pretreatment RPR dilution over 36 months using the Lee-Desu statistic; P < t Number of patients with a reactive RPR titer entering the time interval. 15 June 1991 Annals of Internal Medicine Volume 114 Number
4 these rates were not significant until the 36-month follow-up visit. However, the sample size after 6 months is quite small. Our results are strikingly different from those previously reported (6-12). Some of these studies are based on VDRL results rather than on results from the RPR. The agreement ± 1 dilution between these two tests is reported to be 50%, with the RPR having equal or better sensitivity and specificity (13). Widely quoted studies by Fiumara (6, 7) on the response to syphilis therapy indicate that the rate of seroreversal for primary and secondary syphilis at 12 and 24 months is 100%. Ninety-five percent of patients with early latent disease have also been reported to have seroreverted. An important limitation of these studies was that they reported results on patients treated with therapeutic regimens that differed from those generally accepted. In addition, they defined as re-infected those patients who had a fourfold or greater increase in serologic titers and failed to consider that some of these responses may have been a manifestation of treatment failure. Fiumara has also proposed that any patient with a reactive RPR card test 1 or 2 years after treatment for primary or secondary syphilis should be re-treated (6, 7). Schroeter and colleagues (11) reported that 97% of cases of primary syphilis and 77% of secondary cases seroreverted by 2 years. This study included both initial and repeat infections. Petersen and coworkers (12) similarly reported extremely high seroreversal rates of 97%, 84%, and 73% at 12 months for primary, secondary, and early latent cases, respectively. None of these studies analyzed the serologic response by pretreatment RPR titer. The RPR titer data indicate that successful treatment for primary and secondary syphilis results in a 2- and 3-tube decrease by 6 and 12 months, respectively, for all patients regardless of the initial titer. Patients with early latent syphilis respond much slower with only a 2-tube decrease at 12 and 24 months. These results differ from those of Brown and colleagues (4) who described a 2-tube decline in VDRL titer at 3 months and a 3-tube decline at 6 months. Their study sample included patients both with primary and secondary syphilis who had initial VDRL titers between 1:4 and 1:128. They based their findings on patients who were cured after treatment, with cure defined as the patient being symptom-free after therapy. However, in the natural history of this disease individuals will become symptom-free regardless of therapy. Again, they used therapeutic regimens different from those that are generally accepted. The results of their study (4) concur with ours only in the rate of decline in titer with a more rapid serologic response occurring when the initial titer is high. Seroreversion of treponemal tests was only observed in patients with their first episode of illness. All but three of these seroreversions occurred in patients with primary syphilis. The FTA-Abs test was more likely to become negative then was the MHA-TP test, although the difference was not statistically significant at any time interval. Schroeter and associates (11) reported 6% seroreversion in 80 patients with primary or secondary syphilis at 2 years. In another group of 115 patients with primary syphilis, they showed that the rate of seroreversion depended on the reactivity of the VDRL. Patients with "seronegative VDRL" primary syphilis had a 67% seroreversion rate at 12 months compared with only 11% if the VDRL was initially positive. In another group of 93 patients with secondary syphilis, no FTA-Abs seroreversions were noted. The paper by Schroeter and coworkers reviews patients with initial infection or re-infection and does not differentiate between the two groups (11). The extremely high rate of seroreversion in patients with darkfield-positive, VDRLnegative primary syphilis is difficult to explain, but includes only 18 patients of whom 4 did not have a reactive FTA-Abs test before treatment. In our study, we only included patients with reactive serologic tests. Haas and colleagues (14) recently suggested that the Table 3. Rapid Plasma Reagin (RPR) Titer Decrease by Initial RPR for First Illness Episode by Stage and Time* Stage Initial Titer Time, mo Percentage of Titer Decrease by Number of Tubes (Dilutions) > 4 (Number)t > 3 (Number)t > 2 (Number)t Primary 1: ± 6.7 (43) 65.9 ± 6.2 (34) 76.8 ± 5.4 (28) ± 6.7 (22) 78.5 ± 5.5 (13) 86.7 ± 4.4 (8) ± 6.0 (14) 92.2 ± 3.7 (5) 96.2 ± 2.6 (3) ± 3.2 (174) 69.7 ± 2.9 (143) 79.4 ± 2.5 (101) ± 2.9 (66) 86.0 ± 2.3 (48) 90.5 ± 1.9(35) ± 2.1 (31) 96.6 ± 1.3(17) 98.2 ± 0.9 (8) ± 7.7(35) 71.0 ± 6.8(26) 88.2 ± 4.9 (15) ± 7.2(14) 85.5 ± 5.4 (10) 90.3 ± 4.6 (6) ± 4.6 (7) 92.7 ± 4.0 (4) 97.6 ± 2.3 (2) Secondary ± 5.1 (74) 79.1 ± 4.1 (56) 87.8 ± 3.3 (35) ± 4.7 (22) 88.3 ± 3.4 (14) 93.7 ± 2.6 (6) ± 3.9(12) 95.3 ± 2.3 (8) 98.7 ± 1.2(4) ± 8.7 (26) 81.6 ±6.8 (19) 85.3 ± 6.1 (14) ± 6.8 (6) 93.9 ± 4.2 (3) 94.1 ±4.0(2) Early latent ± 9.5 (14) 30.4 ± 11.4(13) 50.1 ± 11.9(12) ± 12.0(9) 40.3 ±13.5 (7) 77.5 ± 10.8 (4) ± 14.1 (7) 40.3 ± 13.5 (6) 85.0 ± 9.4 (3) * RPR titer decreases are expressed as cumulative proportions ± SE. t Number of patients entering time interval June 1991 Annals of Internal Medicine Volume 114 Number 12
5 Table 4. Cumulative MHA-TP and FTA-Abs Seroreversion after Treatment for First Illness Episode of Primary Syphilis* Test 3 Months 6 Months 12 Months 24 Months 36 Months MHA-TP Cumulative proportion ± SE 3.5 ± ± ± ± ± 2.0 Patients, wt FTA-Abs Cumulative proportion ± SE 3.5 ± ± ± ± ± 4.3 Patients, A?t * MHA-TP = microhemoglutination test for Treponema pallidum; FTA-Abs = fluorescent treponemal antibody absorption test. t Number of patients with a reactive test entering the time interval. FTA-Abs and MHA-TP tests do not reliably identify previous syphilis in HIV-infected individuals as their immune dysfunction progresses and their CD4 counts fall. In a group of 104 HIV-infected men, 18 (17%) showed loss of reactivity of treponemal tests. Univariate predictors for loss of reactivity were symptomatic HIV infection, T4/T8 ratio of 0.6 or less, a single episode of syphilis, and an initial VDRL titer of 1:32 or less. The age of the individual or duration of infection was not significant. However, in a group of 19 HIVnegative men, all had persistent reactivity of treponemal tests up to 8.8 years after infection. The authors did not differentiate between the MHA-TP and FTA-Abs tests, but their results for HIV-negative men are strikingly different from our 3-year follow-up, with 13% and 24% seroreversion of the MHA-TP and FTA-Abs tests, respectively. We stress that treponemal tests will become negative in immunocompetent persons and that negative treponemal tests do not necessarily rule out a past history of syphilis. It should also be recognized that either of the treponemal tests can serorevert individually. Current dogma states that after adequate treatment for primary or secondary syphilis, there should be at least a 2-tube decline in titer by 3 or 4 months and a 4-tube decline by 6 or 8 months, with little or no reaction after the first year. We have shown that the decline in RPR dilutions depends on the illness episode and on the initial titer. For primary syphilis, a 2-tube decline can be expected at 6 months and a 3- and 4-tube decline at 12 and 24 months, respectively. After adequate treatment for secondary syphilis, 3- and 4-tube declines should be observed at 6 and 12 months, respectively. Patients with early latent syphilis should not be expected to have declines of 2 tubes until 12 months. Further, RPR seroreversion at 1 year can be expected in 50% of patients with an initial episode of only primary syphilis. Seroreversion of treponemal tests will be seen after 2 to 3 years of follow-up in up to 24% of patients. Acknowledgments: The authors thank Rose N. Cymbaluk for preparation of the manuscript. Grant Support: By a grant from Health and Welfare Canada. Requests for Reprints: Barbara Romanowski, MD, STD Control, 4th Floor Executive Building, Street, Edmonton, Alberta T5J 1M8, Canada. Current Author Addresses: Drs. Romanowski and Sutherland and Ms. Mooney: STD Control, 4th Floor Executive Building, Street, Edmonton, Alberta T5J 1M8, Canada. Drs. Fick and Love: Department of Community Health Services, Faculty of Medicine, University of Calgary, 3330 Hospital Drive N.W., Calgary, Alberta T2N 4N1, Canada. References 1. WHO Scientific Group on Treponemal Infections. Treponen.1 Infections: Report of a WHO Scientific Group, technical repo t series 674. Geneva: World Health Organization; Willcox RR. Treatment of syphilis. Bull WHO, 1981;59: Division of Venereal Disease: Evaluation of antisyphilitic therapy with intensive follow-up. J Vener Dis 1951;32: Brown ST, Zaidi A, Larsen SA, Reynolds GH. Serological response to syphilis treatment. A new analysis of old data. JAMA. 1985;253: Armitage P, Berry G. Statistical Methods in Medical Research, 2d ed. London: Blackwell Scientific Publications; 1987: Fiumara NJ. Treatment of seropositive primary syphilis: an evaluation of 196 patients. Sex Transm Dis. 1977;4: Fiumara NJ. Treatment of secondary syphilis: an evaluation of 204 patients. Sex Transm Dis. 1977;4: Fiumara NJ. Treatment of early latent syphilis under 1 year's duration: serologic response to treatment of 368 patients. J Am Acad Dermatol. 1986;5: Fiumara NJ. Reinfection primary, secondary, and latent syphilis: the serologic response after treatment. Sex Transm Dis. 1980;7: Fiumara NJ. Treatment of primary and secondary syphilis. Serological response. JAMA. 1980;243: Schroeter AL, Lucas JB, Price EV, Falcone VH. Treatment for early syphilis and reactivity of serologic tests. JAMA. 1972;221: Petersen CS, Jorgensen BB, Pedersen NS. Treatment of early infectious syphilis in Denmark. A retrospective serological study. Dan Med Bull. 1984;31: Perryman MW, Larsen SA, Hambie EA, Pettit DE, Mullally RL, Whittington W. Evaluation of a new rapid plasma reagin card test as a screening test for syphilis. J Clin Microbiol. 1982;16: Haas JS, Bolan G, Larsen SA, Clement MJ, Bacchetti P, Moss AR. Sensitivity of treponemal tests for detecting prior treated syphilis during human immunodeficiency virus infection. J Infect Dis. 1990; 162: June 1991 Annals of Internal Medicine Volume 114 Number
Syphilis Treatment Protocol
STD, HIV, AND TB SECTION Syphilis Treatment Protocol CLINICAL GUIDANCE FOR PRIMARY AND SECONDARY SYPHILIS AND LATENT SYPHILIS www.lekarzol.com (4/2016) Page 1 of 8 Table of Contents Description... 3 Stages
More informationSerological screening for syphilis in HIV-infected individuals: is a non-treponemal test adequate in the era of increasing of new syphilis infections?
Abstract no. WEPE 494 Serological screening for syphilis in HIV-infected individuals: is a non-treponemal test adequate in the era of increasing of new syphilis infections? G.Chrysos 1, D.Karageorgopoulos
More informationSYPHILIS (Treponema pallidum) IMMEDIATE NOTIFICATION STD PROGRAM
SYPHILIS (Treponema pallidum) IMMEDIATE NOTIFICATION STD PROGRAM Event Name: Event Time Period: Clinical Description (CDC 2014) Syphilis 180 days Syphilis is a complex sexually transmitted disease that
More informationtest. It appeared that the MHA-TP test could be
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1983, p. 405-409 0095-1137/83/030405-05$02.00/0 Copyright 1983, American Society for Microbiology Vol. 17, No. 3 Reactivity of Microhemagglutination, Fluorescent
More informationReplaces: 04/13/17. / Formulated: 7/05 SYPHLIS
Effective Date: 81017 Replaces: 041317 Page 1 of 7 POLICY: The Texas Department of Criminal Justice (TDCJ) will identify, test, and manage all offenders with suspected or confirmed syphilis with a uniform
More informationComparison of Doxycycline and Benzathine Penicillin G for the Treatment of Early Syphilis
2017;25(2):107-111 Clinical article Comparison of Doxycycline and Benzathine Penicillin G for the Treatment of Early Syphilis Hailu Xiao *1,2,3, Dianchang Liu *1,2,4, Zhen Li 1,2,4, Rongtao Zheng 1,2,4,
More informationUse of Treponemal Immunoassays for Screening and Diagnosis of Syphilis
Use of Treponemal Immunoassays for Screening and Diagnosis of Syphilis Guidance for Medical Providers and Laboratories in California These guidelines were developed by the California Department of Public
More informationPublic/Private Partnerships: Intervening in the Spread of Syphilis
Public/Private Partnerships: Intervening in the Spread of Diana Torres-Burgos MD, MPH Gerard Castaneda, BSN Alana Thomas, BS STD/HIV Update Conference Grand Rapids, MI 3/11/2014 Outline overview Stages
More informationAnn Dermatol Vol. 29, No. 6, 2017 https://doi.org/ /ad
JI Kim, et al pissn 113-987ㆍeISSN 25-3894 Ann Dermatol Vol. 29, No. 6, 217 https://doi.org/1.521/ad.217.29.6.768 ORIGINAL ARTICLE Serologic Response to Treatment in Human Immunodeficiency Virus-Negative
More informationThe Great Imitator Revealed: Syphilis
The Great Imitator Revealed: Syphilis Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles David Geffen School of Medicine Los Angeles, California Learning
More informationSyphilis. syphilis. Sera from all stages of syphilis and the. to compare dilution titers with those obtained
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 1982, p. 238-242 0095-1137/82/020238-05$02.00/0 Vol. 15, No. 2 Unheated Serum Reagin Test as a Quantitative Test for Syphilis DEBORAH E. PETTIT, SANDRA A. LARSEN,*
More informationEarly syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin
Brief Original Article Early syphilis: serological treatment response to doxycycline/tetracycline versus benzathine penicillin Jun Li, He-Yi Zheng Department of Dermatology and Venereology, Peking Union
More information26. Screening for Syphilis
26. Screening for Syphilis RECOMMENDATION Routine serologic screening for syphilis is recommended for all pregnant women and for persons at increased risk of infection (see Clinical Inter - vention). See
More informationSyphilis Technical Instructions for Civil Surgeons
National Center for Emerging and Zoonotic Infectious Diseases Syphilis Technical Instructions for Civil Surgeons Joanna J. Regan, MD, MPH, FAAP Medical Officer Medical Assessment and Policy Team Immigrant,
More informationEvaluation of a New Rapid Plasma Reagin Card Test as a Screening Test for Syphilis
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1982, p. 286-290 0095-1 137/82/080286-05$02.00/0 Vol. 16, No. 2 Evaluation of a New Rapid Plasma Reagin Card Test as a Screening Test for Syphilis MARY W. PERRYMAN,'*
More information9/9/2015. Began to see a shift in 2012 Early syphilis cases more than doubled from year before
George Walton, MPH, CPH, MLS(ASCP) CM STD Program Manager Bureau of HIV, STD, and Hepatitis September 15, 2015 1 1) Discuss the changing epidemiology of syphilis in Iowa; 2) Explore key populations affected
More information2/13/ Graphic photographs or cartoons used during this presentation might be offensive to some; for this I apologize in advance.
Leon Bullard, MD, MA Medical Consultant, DHEC, DADE The 23 rd Annual APRN Conference Charleston, SC February 24, 2017 1. Provide a brief (very) review of the syphilis story. 2. Define and discuss the stages
More informationLearning Objectives. Syphilis. Lessons. Epidemiology: Disease in the U.S. Syphilis Definition. Transmission. Treponema pallidum
Learning Objectives Syphilis Treponema pallidum 1 Upon completion of this content, the learner will be able to 1. Describe the epidemiology of syphilis in the U.S. 2. Describe the pathogenesis of T. pallidum.
More informationSyphilis Update: New Presentations of an Old Disease
Syphilis Update: New Presentations of an Old Disease Bradley Stoner, MD, PhD Washington University in St. Louis Disclosure: Bradley Stoner, MD, PhD STDs in the United States Where do we stand right now?
More informationNIH Public Access Author Manuscript Clin Infect Dis. Author manuscript; available in PMC 2009 October 1.
NIH Public Access Author Manuscript Published in final edited form as: Clin Infect Dis. 2008 October 1; 47(7): 893 899. doi:10.1086/591534. Normalization of Serum Rapid Plasma Reagin Titer Predicts Normalization
More information6/11/15. BACTERIAL STDs IN A POST- HIV WORLD. Learning Objectives. How big a problem are STIs in the U.S.?
BACTERIAL STDs IN A POST- HIV WORLD Tracey Graney, PhD, MT(ASCP) Monroe Community College Learning Objectives Describe the epidemiology and incidence of bacterial STDs in the U.S. Describe current detection
More informationWHAT DO U KNOW ABOUT STIS?
WHAT DO U KNOW ABOUT STIS? Rattiya Techakajornkeart MD. Bangrak STIs Cluster, Bureau of AIDS, TB and STIs, Department of Disease Control, MOPH, Thailand SEXUALLY TRANSMITTED INFECTIONS? STIs Infections
More informationSYPHILIS. The Great Pretender K. Amen Eguakun, MSN, APRN, AAHIVS
SYPHILIS The Great Pretender K. Amen Eguakun, MSN, APRN, AAHIVS Learning Objectives At the end of this presentation, the participants will be able to 1. Describe the epidemiology of syphilis in the United
More information10/19/2012. Serologic Testing for Syphilis. Disclosures. Comparison of the Traditional and Reverse Screening Algorithms. Outline.
Serologic Testing for Syphilis Comparison of the Traditional and Reverse Screening Algorithms Disclosures Elli S. Theel, Ph.D. Director, Infectious Diseases Serology Laboratory Assistant Professor of Laboratory
More informationSexually Transmitted Diseases Treatment Guidelines, 2015
Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 64 / No. 3 June 5, 2015 Sexually Transmitted Diseases Treatment Guidelines, 2015 U.S. Department of Health and Human Services Centers
More informationLisa Villarroel, MD MPH Medical Director, Division of Public Health Preparedness Arizona Department of Health Services.
Lisa Villarroel, MD MPH Medical Director, Division of Public Health Preparedness Arizona Department of Health Services Disclosures: None 1 PRIMARY Fitzgerald TJ, Cleveland P, Johnson RC et al: Scanning
More informationSexually Transmitted Disease Treatment Tables
Sexually Transmitted Disease Treatment Tables Federal Bureau of Prisons Clinical Practice Guidelines June 2011 Clinical guidelines are made available to the public for informational purposes only. The
More informationSyphilis. sera from the Venereal Disease Serology Laboratory. Serum Bank, Centers for Disease Control, Atlanta,
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 1981, p. 441-445 0095-1137/81/0441-05$02.00/0 Vol. 14, No. 4 Specificity, Sensitivity, and Reproducibility Among the Fluorescent Treponemal Antibody-Absorption Test,
More informationJanuary Dear Physician:
Richard F. Daines, M.D. Commissioner Wendy E. Saunders Executive Deputy Commissioner January 2009 Dear Physician: The purpose of this letter is to bring your attention to the significant increase in reported
More informationNothing to disclose.
Update on Diagnosis and Treatment Lisa Winston, MD University of California, San Francisco/ Zuckerberg San Francisco General Nothing to disclose. 1 This talk will be a little depressing Rising incidence
More informationEvaluation of Reagin Screen, a New Serological Test for Syphilis
JOURNAL OF CUNICAL MICROBIOLoGY, Aug. 1976, p. 145-150 Copyright 1976 American Society for Microbiology Vol. 4, No. 2 Printed in U.S.A. Evaluation of Reagin Screen, a New Serological Test for Syphilis
More informationVDRL v/s TPHA for diagnosis of syphilis among HIV sero-reactive patients in a tertiary care hospital
ISSN: 2319-7706 Volume 3 Number 5 (2014) pp. 726-730 http://www.ijcmas.com Original Research Article VDRL v/s TPHA for diagnosis of syphilis among HIV sero-reactive patients in a tertiary care hospital
More informationClinical Practice Guideline with Delegation of Function
1 of 8 1.0 Purpose 1.1 To improve and focus efforts to treat those at risk for undiagnosed/untreated incubating, primary, secondary, or early latent infectious syphilis. 2.0 Scope and Goal 2.1 Antibiotic
More informationGuidance for Industry
Guidance for Industry Revised Recommendations for Donor and Product Management Based on Screening Tests for Syphilis DRAFT GUIDANCE This document is being distributed for comment purposes only. Submit
More informationBMJ Open. Comparison of the automated rapid plasma reagin (RPR) test versus the conventional RPR card test in syphilis testing
Comparison of the automated rapid plasma reagin (RPR) test versus the conventional RPR card test in syphilis testing Journal: BMJ Open Manuscript ID: bmjopen-0-00 Article Type: Research Date Submitted
More informationAntibodies to Treponema pallidum
APPLIED MICROBIOLOGY, July 1972, p. 26- Copyright 0 1972 American Society for Microbiology Vol. 24, No. 1 Printed in U.S.A. Evaluation of the Qualitative and Automated Quantitative Microhemagglutination
More informationThe Resurgence of Syphilis in British Columbia: Who is affected? What are the challenges? How can we improve our response?
The Resurgence of Syphilis in British Columbia: Who is affected? What are the challenges? How can we improve our response? Gillian Hill-Carroll Travis Salway Hottes Pacific AIDS Network Webinar Series
More informationThis study was undertaken to assess the value
Syphilis Detection in Cerebrovascular Disease Roger E. Kelley, MD, Lynda Bell, RN, Susan E. Kelley, RN, and Shih-Chang Lee, PhD To determine the importance of syphilis testing in cerebrovascular disease,
More informationMichigan Guidelines: HIV, Syphilis, HBV in Pregnancy
Michigan Guidelines: HIV, Syphilis, HBV in Pregnancy Presenter: Theodore B. Jones, MD Maternal Fetal Medicine Wayne State University School of Medicine Beaumont Dearborn Hospital HIV, Syphilis, HBV in
More informationSerologic Response to Treatment in Syphilis
Serologic Response to Treatment in Syphilis 7 Neuza Satomi Sato Center of Immunology, Institute Adolfo Lutz São Paulo, SP Brazil 1. Introduction Serologic monitoring is the way to determine adequate treatment
More informationLearning Objectives. Epidemiology 5/3/2013. Treponema pallidum Diagnosis, Treatment and Prevention. Anne Rompalo, MD, ScM Professor of Medicine
Treponema pallidum Diagnosis, Treatment and Prevention Anne Rompalo, MD, ScM Professor of Medicine Learning Objectives Describe the epidemiology of syphilis in the U.S.Describe the pathogenesis of Treponema
More informationSTDs in HIV Clinical Care: New Guidelines on Treatment and Prevention
STDs in HIV Clinical Care: New Guidelines on Treatment and Prevention Palliative Care Conference Faculty Development Conference August 13, 2015 Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS
More information12/1/2014 GLOBAL HEALTH CASE STUDY RACHEL LE HISTORY OF PRESENT ILLNESS ANY IDEAS? Location: Vadodara, India Gender: female
GLOBAL HEALTH CASE STUDY RACHEL LE HISTORY OF PRESENT ILLNESS Location: Vadodara, India Gender: female Age: 14 years Complains: perforation, anterior hard palate, difficulty eating, difficulty speaking
More informationSyphilis Testing in Northern California Kaiser
Syphilis Testing in Northern California Kaiser Jen Shieh, MS, CLS Test Development Scientist Kaiser Permanente TPMG Regional Laboratory Microbiology Department Kaiser Permanente 3.3 million members 22
More informationAnnual Epidemiological Report
Annual Epidemiological Report November 2018 Key Facts 1 Early infectious syphilis in Ireland, 2017 There were 398 confirmed cases of early infectious syphilis (EIS) notified in 2017 The notification rate
More information5/1/2017. Sexually Transmitted Diseases Burning Questions
Sexually Transmitted Diseases Burning Questions Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles Los Angeles, California FORMATTED: 04-03-17 Financial
More informationDidactic Series. STD Screening & Management: Syphilis. Christian B. Ramers, MD, MPH
Didactic Series STD Screening & Management: Syphilis Christian B. Ramers, MD, MPH Assistant Medical Director Family Health Centers of San Diego Ciaccio Memorial Clinic 3/26/15 ACCREDITATION STATEMENT:
More informationDirect Comparison of the Traditional and Reverse Syphilis Screening Algorithms
JCM Accepts, published online ahead of print on 16 November 2011 J. Clin. Microbiol. doi:10.1128/jcm.05636-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationBURNING & SQUIRMING WHAT S NEW IN SEXUALLY TRANSMITTED INFECTIONS
BURNING & SQUIRMING WHAT S NEW IN SEXUALLY TRANSMITTED INFECTIONS Dr. Joss Reimer MD MPH FRCPC Medical Officer of Health, WRHA & Manitoba Health Assistant Professor, Departments of Community Health Sciences
More informationDivision of Dermatology Dr A Motau
Division of Dermatology Dr A Motau CASE 1 Histopathology H&E H&E H&E Wartin Starry Immunohistochemical stain for T. pallidum Investigations FBC, U&E, LFT Normal T. pallidum Abs Reactive RPR screen
More informationSYPHILIS (REPORTABLE)
SYPHILIS (REPORTABLE) PREAMBLE In BC, the diagnosis of syphilis is determined by the BCCDC Provincial STI/HIV Clinic physician directly or in coordination with the*physician or nurse practitioner (NP)
More informationCHAPTER-X SYPHILIS R.KAVITHA, M.PHARM, LECTURER, DEPARTMENT OF PHARMACEUTICS, SRM COLLEGE OF PHARMACY, SRM UNIVERSITY, KATTANKULATHUR.
CHAPTER-X SYPHILIS R.KAVITHA, M.PHARM, LECTURER, DEPARTMENT OF PHARMACEUTICS, SRM COLLEGE OF PHARMACY, SRM UNIVERSITY, KATTANKULATHUR. Trepanoma pallidum D. Clinical Infection: Syphilis Transmission Usually
More informationEdward W. Hook, III, M.D.
Challenging Cases Edward W. Hook III M.D. Professor and Director Division of Infectious Diseases University of Alabama at Birmingham And PI, Alabama/North Carolina STD PTC Edward W. Hook, III, M.D. Grant/Research
More informationFrequent Screening for Syphilis as Part of HIV Monitoring Increases the Detection of Early Asymptomatic Syphilis Among HIV-Positive Homosexual Men
CLINICAL SCIENCE Frequent Screening for Syphilis as Part of HIV Monitoring Increases the Detection of Early Asymptomatic Syphilis Among HIV-Positive Homosexual Men Melanie Bissessor, FRACGP,* Christopher
More informationMID 15. Syphilis. Simon Tsiouris, MD, MPH. 1. Introduction
Syphilis Simon Tsiouris, MD, MPH 1. Introduction Syphilis is a chronic infection caused by the bacterium Treponema pallidum which was first described over 500 years ago. The manifestations of disease are
More informationEmerging Issues in STDs and Resistance
Emerging Issues in STDs and Resistance Toye H. Brewer, MD Asst. Professor of Clinical Medicine University of Miami School of Medicine Co-Director- Fogarty International Training Program Outline Syphilis-
More informationSusanne Norris Zanto, MPH, MLS (ASCP) CM, SM Montana Public Health Laboratory
Susanne Norris Zanto, MPH, MLS (ASCP) CM, SM Montana Public Health Laboratory Describe the challenges in syphilis diagnostics Present two testing algorithms Non-treponemal test as initial screen Treponemal
More informationRevisions to the Syphilis Surveillance Case Definitions, 2018
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Revisions to the Syphilis Surveillance Case Definitions, 2018 Sarah Kidd, MD, MPH Medical Epidemiologist Division of STD Prevention
More informationSEXUALLY TRANSMITED DISEASES SYPHILIS ( LUES ) Dr D. Tenea Department of Dermatology University of Pretoria
SEXUALLY TRANSMITED DISEASES SYPHILIS ( LUES ) Dr D. Tenea Department of Dermatology University of Pretoria INTRODUCTION Venereal disease = old term STD infections transmitted by sexual contact Sexually
More informationInfectious syphilis in Canada:
30 CCDR 05 February 2015 Volume 41-2 https://doi.org/10.14745/ccdr.v41i02a03 Infectious syphilis in Canada: 2003-2012 Totten S 1,*, MacLean R 1, Payne E 1 1 Centre for Communicable Diseases and Infection
More informationChapter 11. Sexually Transmitted Diseases
Chapter 11. Sexually Transmitted Diseases General Guidelines Persons identified as having one sexually transmitted disease (STD) are at risk for others and should be screened as appropriate. Partners of
More informationTo view an archived recording of this presentation please click the following link:
To view an archived recording of this presentation please click the following link: http://pho.adobeconnect.com/p16lj8z0qm3/ Please scroll down this file to view a copy of the slides from the session.
More informationSexually transmitted infections (in women)
Sexually transmitted infections (in women) Timothy Kremer, MD Assistant Professor, Department of Obstetrics and Gynecology University of North Texas Health Science Center Last official CDC guidelines:
More informationCATIE Webinar Series (Part 1) Gay Men s Health & HIV Prevention in Canada
CATIE Webinar Series (Part 1) Gay Men s Health & HIV Prevention in Canada The Rising Tide of Syphilis: Update on Syphilis among Gay, Bisexual, Two-Spirit and other MSM in Canada Wednesday, February 22nd,
More informationSyphilis Outbreak Investigation Report
` Office of the Chief Medical Officer of Health Syphilis Outbreak Investigation Report Office of the Chief Medical Officer of Health Health il 2014 Table of Contents Summary... 1 Acronyms... 1 Introduction...
More informationALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES
ALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES A. Screening Page Chlamydia and Gonorrhea 1 HIV 1 Syphilis 1 Genital Herpes 2 Hepatitis A 2 Hepatitis B 2 Hepatitis
More informationSex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046)
Sex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046) Kenneth A. Katz, MD, MSc, MSCE Dermatologist, Kaiser Permanente, San Francisco, CA AAD Annual Meeting, San Diego, CA February
More informationSexually transmitted infections (in women)
Sexually transmitted infections (in women) Timothy Kremer, MD Assistant Professor, Department of Obstetrics and Gynecology University of North Texas Health Science Center Last official CDC guidelines:
More informationManagement of Syphilis in Patients with HIV
Management of Syphilis in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the Guideline Increase the numbers of NYS
More informationSyphilis Screening and Prevalence: Past, Present, Future
Syphilis Screening and Prevalence: Past, Present, Future Allison Haynes, MD University of Kansas School of Medicine- Wichita Family Medicine Residency at Smoky Hill- Salina 1 https://www.cdc.gov/std/syphilis/images/treponema-pallidum.htm
More information4/18/2018. Syphilis Testing. Disclosure. Learner Objectives. Outline. Employee and stockholder of Bio-Rad Laboratories, Inc.
Disclosure Employee and stockholder of Bio-Rad Laboratories, Inc. Unraveling the Complexities of Syphilis Testing Maria Crisostomo, April 30 & May 1, 2018 2 Learner Objectives Syphilis Testing Upon completion
More informationBacteriology. Spirochetes. Three important genera: 1. Treponema 2. Borrelia 3. Leptospira. Treponema pallidum. Causes syphilis.
Bacteriology Spirochetes Three important genera: 1. Treponema 2. Borrelia 3. Leptospira Treponema pallidum Causes syphilis Organism: - Spirochetes with 6-14 regularly spaced spirals - Its length is the
More informationNeurosyphilis as an Emerging Feature in the HIV Setting. Christina M. Marra, MD University of Washington Seattle, WA, USA
Neurosyphilis as an Emerging Feature in the HIV Setting Christina M. Marra, MD University of Washington Seattle, WA, USA Syphilis in the Developing World Region 1995 1999 Sub-Saharan 3,530,000 3,828,000
More informationThe U.S. Preventive Services Task Force (USPSTF) makes
Annals of Internal Medicine Clinical Guidelines Screening for Syphilis Infection in Pregnancy: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement U.S. Preventive Services Task Force*
More informationA few studies of the MHA-TP in animals with. experimental treponemal infections have been
Br J Vener Dis 1980; 56:291-6. Quantitative microhaemagglutination assay for Treponema pallidum antibodies in experimental syphilis ROBERT R TIGHT AND ARTHUR C WHITE From the Division of Infectious Diseases,
More informationEvaluation of a Treponema pallidum Enzyme Immunoassay as a Screening Test for Syphilis
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, JUly 1994, p. 477-481 Vol. 1, No. 4 1071-412X/94/$04.00+0 Copyright C 1994, American Society for Microbiology Evaluation of a Treponema pallidum Enzyme Immunoassay
More informationMedical Bacteriology Lecture 11
Medical Bacteriology Lecture 11 Spirochaetaceae Treponema Borrelia 1 Spirochaetaceae Characteristics - Gran negative rods - spiral single cells, or cork-screw-shaped, extremely thin and can be very long
More informationBackground. Restricted Siemens Healthcare GmbH, >1 year Late latent syphilis. Restricted Siemens Healthcare GmbH, 2017
Background Nonneutralizing The Evolution of Syphilis Testing: Clinical Benefits of a Reverse Screening Algorithm Katherine Soreng PhD Lafond RE, et al. Clin Microbiol Rev. 06;19(1):29 49. Disease course:
More informationProfessor Adrian Mindel
Causes of genital ulceration viruses and others Professor Adrian Mindel University of Sydney VIM 16 th August 2012 Outline Definition Causes Epidemiology Diagnosis Definition of genital ulcer A defect
More informationfor Syphilis visualize the antigen-antibody reaction. Procedures
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1983, p. 1141-1145 0095-1137/83/111141-05$02.00/0 Copyright X 1983, American Society for Microbiology Vol. 18, No. 5 Toluidine Red Unheated Serum Test, a Nontreponemal
More informationDiscordant Results from Reverse Sequence Syphilis Screening Five Laboratories, United States,
Please note: An erratum has been published for this issue. To view the erratum, please click here. Morbidity and Mortality Weekly Report Weekly / Vol. 60 / No. 5 February 11, 2011 Discordant Results from
More informationPerformance Characteristics of the Reverse Syphilis Screening Algorithm in a Population With a Moderately High Prevalence of Syphilis
Performance Characteristics of the Reverse Syphilis Screening Algorithm in a Population With a Moderately High Prevalence of Syphilis Angela R. Rourk, Frederick S. Nolte, PhD, and Christine M. Litwin,
More informationAnalysis of 3 Algorithms for Syphilis Serodiagnosis and Implications for Clinical Management
MAJOR ARTICLE Analysis of 3 Algorithms for Syphilis Serodiagnosis and Implications for Clinical Management Man-Li Tong, 1,a Li-Rong Lin, 1,2,a Li-Li Liu, 1,2,3,a Hui-Lin Zhang, 1 Song-Jie Huang, 1 Yu-Yan
More informationSyphilis Tests in Diagnostic and Therapeutic Decision Making
DIAGNOSIS AND TREATMENT Diagnostic Decision Syphilis Tests in Diagnostic and Therapeutic Decision Making GAVIN HART, M.D., M.P.H.; Adelaide, South Australia, Australia Predictive value calculations were
More informationSummary Guidelines for the Use of Herpes Simplex Virus (HSV) Type 2 Serologies
Summary Guidelines for the Use of Herpes Simplex Virus (HSV) Type 2 Serologies Genital herpes is one of the most prevalent sexually transmitted diseases, affecting more than one in five sexually active
More informationSTD Essentials for the Busy Clinician. Stephanie E. Cohen, MD, MPH
STD Essentials for the Busy Clinician Stephanie E. Cohen, MD, MPH Assistant Professor, Division of Infectious Diseases, UCSF Medical Director, City Clinic San Francisco Department of Public Health Disclosures
More informationINFECTIOUS SYPHILIS NOTIFICATION FORM
INFECTIOUS SYPHILIS NOTIFICATION FORM This is a Schedule 1, Section C disease notifiable to the Medical Officer of Health under Sections 74 and 74AA of the Health Act 1956 using non-identifiable data.
More informationSyphilis in the 21 st Century: Sex, Sores, Science, and Surveillance. Syphilis in Men
Syphilis in the 21 st Century: Sex, Sores, Science, and Surveillance Syphilis in Men Kenneth A. Katz, MD, MSc, MSCE Kaiser Permanente, San Francisco, CA AAD Annual Meeting Washington, D.C. March 2, 2019
More informationClinical Practice Objectives
STD Essentials for the Busy Clinician Susan S. Philip, MD, MPH Assistant Professor, Division of Infectious Diseases, UCSF Director, STD Prevention and Control Services San Francisco Department of Public
More informationCAP Laboratory Improvement Programs. Prevalence of Traditional and Reverse-Algorithm Syphilis Screening in Laboratory Practice
CAP Laboratory Improvement Programs Prevalence of Traditional and Reverse-Algorithm Syphilis Screening in Laboratory Practice A Survey of Participants in the College of American Pathologists Syphilis Serology
More informationInt.J.Curr.Microbiol.App.Sci (2018) 7(8):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 08 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.708.085
More informationNotifiable Sexually Transmitted Infections 2009 Annual Report
Notifiable Sexually Transmitted Infections 29 Annual Report 21 Government of Alberta Alberta Health and Wellness, Surveillance and Assessment Send inquiries to: Health.Surveillance@gov.ab.ca Notifiable
More informationSYPHILITIC SEROREACTIVITY AMONG THE THAI POPULATION AGED 50 YEARS AND ABOVE : VALUE OF MASS SCREENING
SYPHILITIC SEROREACTIVITY AMONG THE THAI POPULATION AGED 50 YEARS AND ABOVE : VALUE OF MASS SCREENING Sutthichai Jitapunkul Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok
More informationMedicine. Observational Study. 1. Introduction OPEN
Observational Study Medicine Could lengthening minocycline therapy better treat early syphilis? Li-Li Shao, MM, Rui Guo, MM, Wei-Jie Shi, MM, Yuan-Jun Liu, MD, Bin Feng, MB, Long Han, MB, Quan-Zhong Liu,
More informationTEN YEARS OF SYPHILIS TRENDS IN THE NORTHERN CAPE PROVINCE, SOUTH AFRICA, UTILISING THE NHLS CORPORATE DATA WAREHOUSE
TEN YEARS OF SYPHILIS TRENDS IN THE NORTHERN CAPE PROVINCE, SOUTH AFRICA, UTILISING THE NHLS CORPORATE DATA WAREHOUSE Introduction Ngormbu Ballah 1,2,3, Lazarus Kuonza 1,3, Gloria De Gita 2, Alfred Musekiwa
More informationSex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046)
Sex, Sores, Science, and Surveillance: Syphilis in the 21 st Century (U046) Kenneth A. Katz, MD, MSc, MSCE Dermatologist, Kaiser Permanente, San Francisco, CA AAD Annual Meeting, Orlando, FL March 4, 2017
More informationEVALUATION OF ENZYME IMMUNOASSAY AND IMMUNOBLOT TESTING FOR THE DIAGNOSIS OF SYPHILIS IN ALBERTA
EVALUATION OF ENZYME IMMUNOASSAY AND IMMUNOBLOT TESTING FOR THE DIAGNOSIS OF SYPHILIS IN ALBERTA Arto Ohinmaa, Anderson Chuck, Thanh Nguyen, Janice Varney, Philip Jacobs Supported by a financial contribution
More informationCurrent standards for diagnosis and treatment of syphilis: selection of some practical issues, based on the European (IUSTI) and U.S.
Special paper Current standards for diagnosis and treatment of syphilis: selection of some practical issues, based on the European (IUSTI) and U.S. (CDC) guidelines Maciej Pastuszczak, Anna Wojas-Pelc
More information